TEVA(US:TEVA) Globenewswire·2025-12-12 21:30Core Viewpoint - Teva Pharmaceutical Industries Ltd. is preparing to release its Q4 2025 results on January 28, 2026, and has made an Aide Memoire available to assist investors in understanding the company's performance and outlook [1][2]. Group 1: Company Overview - Teva is transforming into a leading innovative biopharmaceutical company, supported by a strong generics business [3]. - The company has a long-standing commitment of over 120 years to innovate in neuroscience, immunology, and provide complex generic medicines, biosimilars, and pharmacy brands globally [3]. - Teva emphasizes its dedication to addressing patients' needs both now and in the future [3]. Group 2: Upcoming Financial Results - The Q4 2025 Aide Memoire is based on prior results, management commentary, and data from independent sources to prepare investors for the upcoming financial results [2]. - The Q4 2025 results are scheduled to be released at 7am ET, followed by a conference call at 8am ET on January 28, 2026 [2].